PharmaResearch Surpasses Sales of 10 Million cc for REJURAN®
Achieving the result
based on the product’s effectiveness and safety ... planning to focus more on
expanding markets at home and abroad
PharmaResearch (CEOs: Ki Seock Kang, ThinKyou
Kim), a biopharmaceutical company, announced that REJURAN®, a PN-based medical
device, had surpassed the 10 million cc sales mark earlier this month.
As a medical device for facial-wrinkle
reduction made by applying the company’s patented DOT™ (DNA Optimizing Technology) PN (Polynucleotide) technology, REJURAN®
has been used by more than 500,000 people every year since its launch in 2014,
which is considered the first achievement among PN-based skin booster products.
Based on its strong position in the domestic
market, REJURAN® is actively targeting overseas markets. PharmaResearch has
registered and sold products in more than 30 countries around the world,
including Asia, North America, Europe, and the Middle East, with a more than
51% CAGR in export since 2019.
“The cumulative sales of 10 million cc is a testament to the product’s superior effectiveness and high safety profile,” said PharmaResearch. “We
will continue to develop various marketing programs to help consumers around
the world experience REJURAN in line with the K-beauty trend.”
ParmarResearch is a regenerative medicine-based bio-pharma company that produces and sells pharmaceuticals, medical devices, cosmetics, and health supplements based on its tissue regeneration technologies DOT™PDRN and DOT™PN. The company offers a range of products, including REJURAN®, CONJURAN®, REJURAN Cosmetics, and Re-An® Eye Drops.